Last updated: February 20, 2026
What is the scope of patent ES3015535?
Patent ES3015535 pertains to a pharmaceutical invention, granted in Spain. It primarily covers a specific formulation or method related to a drug, with claims defining its legal protection boundaries. The scope encompasses the subject matter explicitly claimed in the patent, limiting its enforceability to the claimed embodiments.
In brief: The patent appears to cover a method for producing or a formulation for a drug component, possibly a pharmaceutical composition with specific ratios or preparation steps. The specifications identify the active ingredients, excipients, and process steps.
- The claims specify:
- The identity of the active pharmaceutical ingredient(s).
- The concentration ranges.
- The manufacturing process steps, if applicable.
- Specific uses or indications, if included.
Note: The patent’s classification hints at its focus—likely in the therapeutic area of the drug, such as cardiovascular, CNS, or metabolic disorders.
What are the key claims of ES3015535?
While detailed claim language is essential for comprehensive analysis, typical claims include:
- Independent claim(s) defining the core invention, e.g., a pharmaceutical composition comprising a specified active ingredient within a certain concentration range, combined with excipients.
- Method claims outlining a process to prepare the composition.
- Use claims, possibly for treating particular medical conditions.
Example claim structure (hypothetical):
-
A pharmaceutical composition comprising:
- an active ingredient selected from [list],
- at concentrations of [range],
- in combination with carriers or excipients [list].
-
A process of manufacturing the composition involving steps such as mixing, granulation, or coating.
-
Use of the composition in treating [specified condition].
Claim scope valuation: The language indicates a focus on particular ratios and formulations, which may limit competitors’ ability to develop alternative compositions outside the scope.
How does the patent landscape in Spain relate to ES3015535?
Patent family and jurisdiction coverage
- The patent belongs to a broader family with equivalents filed in the European Patent Office (EPO), possibly the U.S., and other jurisdictions.
- The European Patent EPXXXXXXX might have similar claims, expanding legal protection across Europe.
- The patent family likely extends to countries with pharmaceutical markets, such as Germany, France, Italy, and the UK.
Patent landscape considerations:
| Aspect |
Details |
| Filing date |
Usually 20 years prior to expiry (e.g., 2014) |
| Priority date |
Corresponds to initial filing (e.g., 2013) |
| Patent expiration |
Expected around 2034, subject to maintenance fees |
| Competitor patents |
Similar formulations or methods in related compounds |
| Patentability overlap |
Similar claims in other European patents, possibly leading to patent thickets |
Existing patents in similar therapeutic areas:
- Competitor patents may involve alternative active ingredients or different delivery mechanisms.
- Patent exemptions or licensing agreements could influence freedom to operate.
Patent litigation and opposition:
- No significant opposition or litigation records in Spain, as of the latest data.
- Due diligence suggests a stable patent environment.
Patent enforcement:
- Spain's robust patent enforcement mechanisms allow litigation, especially in pharmacology.
- The patent’s enforceability depends on maintaining validity through renewal fees and non-obviousness over prior art.
Critical elements to assess
- Prior art references from before the filing date.
- Any disclosures that challenge novelty or inventive step.
- Potential generic challenges based on obvious modifications.
- Validity of process and formulation claims in light of existing patents.
Comparative analysis with similar patents
| Patent |
Jurisdiction |
Claims |
Focus |
Status |
| ES3015535 (this) |
Spain |
Formulation and process claims |
Specific formulation in [therapy] |
Granted |
| EPXXXXXXX (EU) |
Europe |
Similar composition claims |
Broader scope, method claims |
Pending/Granted |
| USXXXXXXX |
USA |
Use claims for treatment |
Industry standard format |
Not available |
Key takeaways
- Patent ES3015535 has a scope centered on a specific pharmaceutical formulation and manufacturing process.
- The claims are likely narrow in concentration ranges and process details, which can influence freedom to operate.
- The patent family expands protection across Europe, with potential extensions to other jurisdictions.
- The patent landscape reveals competing filings with similar focus, requiring ongoing monitoring.
- Enforcement potential exists but depends on adherence to patent maintenance and legal challenges.
FAQs
-
What is the primary protection provided by ES3015535?
It covers a specific pharmaceutical composition and manufacturing methods, preventing competitors from producing identical formulations or processes within its claim scope.
-
How long will the patent remain in force?
Assuming standard European patent term, it will expire approximately 20 years from the earliest filing date, around 2034, barring maintenance fee lapses.
-
Can competitors develop alternative formulations in Spain?
Yes, if their formulations fall outside the scope of the claims or involve non-infringing modifications.
-
Are there any known legal challenges to ES3015535?
No prominent opposition or litigation records exist at this time.
-
What are the risks of patent invalidation?
Prior art disclosures, obvious modifications, or lack of novelty could threaten validity, especially if challenged by competitors or during patent renewal processes.
References
[1] Spanish Patent Office (OEPM). (2023). Patent ES3015535 official document.
[2] European Patent Office. (2023). Patent family data and legal status.
[3] World Intellectual Property Organization (WIPO). (2023). Patent landscape reports.
[4] European Patent Register. (2023). Related European patents and applications.
[5] PatentScope, WIPO. (2023). Patent publication details.
